Soft Discoidal Polymeric Nanoconstructs Resist Macrophage Uptake and Enhance Vascular Targeting in Tumors.

Most nanoparticles for biomedical applications originate from the self-assembling of individual constituents through molecular interactions and possess limited geometry control and stability. Here, 1000 × 400 nm discoidal polymeric nanoconstructs (DPNs) are demonstrated by mixing hydrophobic and hydrophilic polymers with lipid chains and curing the resulting paste directly within silicon templates. By changing the paste composition, soft- and rigid-DPNs (s- and r-DPNs) are synthesized exhibiting the same geometry, a moderately negative surface electrostatic charge (-14 mV), and different mechanical stiffness (∼1.3 and 15 kPa, respectively). Upon injection in mice bearing nonorthotopic brain or skin cancers, s-DPNs exhibit ∼24 h circulation half-life and accumulate up to ∼20% of the injected dose per gram tumor, detecting malignant masses as small as ∼0.1% the animal weight via PET imaging. This unprecedented behavior is ascribed to the unique combination of geometry, surface properties, and mechanical stiffness which minimizes s-DPN sequestration by the mononuclear phagocyte system. Our results could boost the interest in using less conventional delivery systems for cancer theranosis.

[1]  M. Uesaka,et al.  Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.

[2]  X. Zhao,et al.  Lithographically defined uniform worm-shaped polymeric nanoparticles , 2010, Nanotechnology.

[3]  Matthew D. McDermott,et al.  The hydrogel template method for fabrication of homogeneous nano/microparticles. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[4]  Paolo Decuzzi,et al.  On the near-wall accumulation of injectable particles in the microcirculation: smaller is not better , 2013, Scientific Reports.

[5]  Samir Mitragotri,et al.  Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[6]  Samir Mitragotri,et al.  Control of endothelial targeting and intracellular delivery of therapeutic enzymes by modulating the size and shape of ICAM-1-targeted carriers. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  S. Gambhir,et al.  Molecular imaging in living subjects: seeing fundamental biological processes in a new light. , 2003, Genes & development.

[8]  Warren C W Chan,et al.  Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes. , 2007, Nano letters.

[9]  S. V. Sreenivasan,et al.  Mammalian cells preferentially internalize hydrogel nanodiscs over nanorods and use shape-specific uptake mechanisms , 2013, Proceedings of the National Academy of Sciences.

[10]  Ashutosh Chilkoti,et al.  Nanomaterials for Drug Delivery , 2012, Science.

[11]  Li Shi,et al.  Nanoimprint lithography based fabrication of shape-specific, enzymatically-triggered smart nanoparticles. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[12]  Warren C W Chan,et al.  The effect of nanoparticle size, shape, and surface chemistry on biological systems. , 2012, Annual review of biomedical engineering.

[13]  S. Wise Nanocarriers as an emerging platform for cancer therapy , 2007 .

[14]  Jinming Gao,et al.  Polymeric Nanomedicine for Cancer MR Imaging and Drug Delivery , 2009 .

[15]  M. Ferrari Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[16]  J Szebeni,et al.  Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. , 2003, Progress in lipid research.

[17]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[18]  M A Fischl,et al.  Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Ji Guo,et al.  Nanofabricated particles for engineered drug therapies: a preliminary biodistribution study of PRINT nanoparticles. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[20]  Mauro Ferrari,et al.  The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. , 2009, Biomaterials.

[21]  M. Steven Greene,et al.  Quantifying uncertainties in the microvascular transport of nanoparticles , 2014, Biomechanics and modeling in mechanobiology.

[22]  Michael Hawkins,et al.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Ralph Weissleder,et al.  Multifunctional magnetic nanoparticles for targeted imaging and therapy. , 2008, Advanced drug delivery reviews.

[24]  Ying Liu,et al.  Cellular uptake, intracellular trafficking, and cytotoxicity of nanomaterials. , 2011, Small.

[25]  Vladimir P Torchilin,et al.  Multifunctional nanocarriers. , 2006, Advanced drug delivery reviews.

[26]  Anne L. van de Ven,et al.  Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions. , 2013, Nature nanotechnology.

[27]  J. V. Von Roenn,et al.  Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  M. Ferrari,et al.  Intracellular trafficking of silicon particles and logic-embedded vectors. , 2010, Nanoscale.

[29]  L. Lartigue,et al.  Biodegradation of iron oxide nanocubes: high-resolution in situ monitoring. , 2013, ACS nano.

[30]  R. Jain,et al.  Delivering nanomedicine to solid tumors , 2010, Nature Reviews Clinical Oncology.

[31]  Igor Sokolov,et al.  Method for quantitative measurements of the elastic modulus of biological cells in AFM indentation experiments. , 2013, Methods.

[32]  E. Cosgriff-Hernandez,et al.  Determination of the in vivo degradation mechanism of PEGDA hydrogels. , 2014, Journal of biomedical materials research. Part A.

[33]  K. Beningo,et al.  Fc-receptor-mediated phagocytosis is regulated by mechanical properties of the target. , 2002, Journal of cell science.

[34]  Mauro Ferrari,et al.  Intravascular Delivery of Particulate Systems: Does Geometry Really Matter? , 2008, Pharmaceutical Research.

[35]  Samir Mitragotri,et al.  Polymer particle shape independently influences binding and internalization by macrophages. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[36]  Joseph M. DeSimone,et al.  Using mechanobiological mimicry of red blood cells to extend circulation times of hydrogel microparticles , 2011, Proceedings of the National Academy of Sciences.

[37]  Joseph M. DeSimone,et al.  Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.

[38]  Mauro Ferrari,et al.  Rapid tumoritropic accumulation of systemically injected plateloid particles and their biodistribution. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[39]  M. Ferrari,et al.  Discoidal Porous Silicon Particles: Fabrication and Biodistribution in Breast Cancer Bearing Mice , 2012, Advanced functional materials.

[40]  Mauro Ferrari,et al.  Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. , 2008, Nature nanotechnology.

[41]  Mary E Napier,et al.  More effective nanomedicines through particle design. , 2011, Small.

[42]  R. Jain,et al.  Strategies for advancing cancer nanomedicine. , 2013, Nature materials.

[43]  M Ferrari,et al.  Size and shape effects in the biodistribution of intravascularly injected particles. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[44]  E Kent Yucel,et al.  MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325. , 2005, Radiology.

[45]  Stephanie E. A. Gratton,et al.  The effect of particle design on cellular internalization pathways , 2008, Proceedings of the National Academy of Sciences.

[46]  M. Bawendi,et al.  Renal clearance of quantum dots , 2007, Nature Biotechnology.

[47]  Robert Langer,et al.  Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform. , 2008, ACS nano.

[48]  Dong Chen,et al.  The shape effect of mesoporous silica nanoparticles on biodistribution, clearance, and biocompatibility in vivo. , 2011, ACS nano.

[49]  S. Mitragotri,et al.  Elasticity of nanoparticles influences their blood circulation, phagocytosis, endocytosis, and targeting. , 2015, ACS nano.

[50]  Samir Mitragotri,et al.  Physical approaches to biomaterial design. , 2009, Nature materials.